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Abstract	
Background: It is evident that oxidative stress plays a crucial role in etiology of multiple sclerosis (MS). 
Dysregulation of antioxidant enzymes have been implicated in demylination and neuronal loss in MS. The aim of 
this study was to evaluate mRNA expression and activity of manganese superoxide dismutase (MnSOD), and 
catalase in peripheral blood mononuclear cells (PBMCs) from patients with relapsing-remitting multiple sclerosis 
(RRMS) and healthy controls. Materials and Methods: We recruited 20 RRMS patients and 20 age-and sex-
matched healthy subjects. PBMCs were isolated, RNA was extracted and real time-PCR was used to evaluate 
mRNA expression of MnSOD and catalase. Enzyme activity of MnSOD and catalase were measured using 
colorimetric assays. Results: We found a significant increase in mRNA expression and activity of catalase in 
PBMCs from patients compared with controls, which was accompanied by reduced activity and expression of 
MnSOD in MS patients. Conclusion: It appears that impaired antioxidant enzymes in term of high activity of 
catalase and decreased activity of MnSOD are involved in MS pathogenesis, however further studies are needed to 
establish this concept. 
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Multiple sclerosis (MS), the most common 
cause of disability in young adults, is thought to be a 
chronic inflammatory disease characterized by the 
presence of scattered focal demyelinated lesions in 
both white and gray matter in all stages of disease [1, 
2]. It is also well-documented that clinical 
heterogeneity is characteristics of MS and one more 
mechanism is dominant in various clinical course of 
disease [3]. 
Although the etiology of MS has not been 
clearly elucidated, evidence has been emerging that 
several pathological processes including demylination 
and axonal loss play a crucial role in MS pathogenesis 
[4, 5]. Numerous studies have demonstrated that 
oxidative stress, resulting from imbalance between 
reactive oxygen species (ROS) production and 
neutralization, is a well-recognized mechanism in the 
initiation and progression of MS [6]. The anti-oxidant 
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deficiency and high level of oxidative stress 
biomarkers have been extensively demonstrated in 
MS patients and also experimental allergic 
encephalomyelitis experimental autoimmune 
encephalitis (EAE), a widely used animal model for 
MS [7-9].   
Oxidative stress activates the oxidative stress-
defense system to protect cells against deleterious 
impacts of ROS against tissue damage and to 
preserve redox balance. The nuclear factor-E2-
related factor (Nrf2) antioxidant response element 
(ARE) pathway is a crucial part of system encoding 
antioxidant enzymes. Nrf2  is connected to the  actin-
bound Kelch-like ECH-associated protein 1  (Keap1) 
in the cytoplasm in physiological conditions, 
however  in situations linked to high production of 
ROS, Nrf2 separates from Keap1 and translocates to 
the nucleus, which in turn lead to transcription 
activation of ARE-regulated genes [10, 11]. 
Superoxide dismutases (SODs), peroxiredoxins  
(Prxs), heme oxygenases (HOs), glutathione  
peroxidases  (GPxs), and catalase  are  well-known  
Nrf2–ARE-driven genes involved antioxidant  
defense system [11]. It is of particular importance 
that up regulation superoxide dismutase and catalase 
via inducers or viral vectors have been linked to  
improve disease severity in EAE [11, 12].  
The superoxide dismutases (SODs) and 
catalase comprise the first line of oxidative stress 
defense system against ROS. SODs catalyze the 
dismutation of the superoxide radical to oxygen 
and hydrogen peroxide and catalase is accountable 
for converting the hydrogen peroxide to water and 
oxygen. Impaired activity of MnSOD and catalase 
has been associated with uncontrolled production of 
ROS and other free radicals.  
It has been suggested that oxidative stress may 
take precedence over inflammatory responses in MS 
patients. In other hand, the infiltration of 
inflammatory cells including T-lymphocytes and 
monocyte-derived macrophages into CNS and 
consequently production of large amounts of ROS is 
believed to have an important role in neuronal 
damage, oligodendrocyte loss and myelin 
phagocytosis in MS [4, 13, 14]. Therefore, it is 
rational that peripheral blood mononuclear cells 
(PBMCs) as a mixed population of 
immunocompetent cells can be considered as a 
plausible cellular model in order to evaluate enzymes 
involved in oxidative stress defense system in MS.  
Despite numerous studies examining the gene 
expression and enzyme activity of antioxidant 
enzymes in MS patients[14,15], To our knowledge to 
date no study has been investigated MnSOD and 
catalase mRNA expression and enzyme activity in MS 
in PBMC as a readily available source .Hence, we 
aimed at evaluating the MnSOD and catalase mRNA 
expression and enzyme activity in PBMCs isolated 
from MS patients compared with healthy subjects. 
Methods	
Patients and control subjects. The population 
study consisted of 20 MS  patients in relapsing-
remitting course of disease (RRMS) and 20 healthy 
subjects. The patients and healthy subjects in this case-
control study was between the ages of 20-40 years and 
were matched in term of age and gender. The patients 
were recruited from Sina MS Center, Sina Hospital 
,Tehran University of Medical Science, Tehran, Iran 
and all patients were diagnosed by a neurologist based  
on the McDonald criteria. All patients had an 
Expanded Disability Status Scale (EDSS) score≤ 6 and 
had never received any immunomodulatory and 
immunosuppressive drugs (n=12) and eight  patients 
were not treated with any immunomodulatory and 
immunosuppressive drugs during previous 6 month. 
The control group were selected among healthy 
subjects with no family history of MS and other 
autoimmune diseases. The inclusion  criteria  for  both  
groups were: 1. not received any  types of antioxidant 
supplements, anti-inflammatory drugs, and vitamins in 
the previous 6 months; 2. had no history of acute or 
chronic infection, malignancy, diabetes, and any 
clinically significant systemic disease. 
The study was approved by the Ethics 
Committee of Tehran University of Medical Sciences, 
and we obtained informed written consents from both 
cases and controls, prior to the study. The peripheral 
blood samples were taken in heparin-treated tubes 
after an overnight fast and were immediately used for 
PBMC isolation. 
PBMC isolation, RNA extraction and cDNA 
synthesis. PBMCs were separated using density-
gradient centrifugation by Ficoll-Hypaque 
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(Lympholyte-H; Cedarlane Laboratories, Hornby, 
ON, Canada), washed twice with PBS ,and stored in 
70°C to evaluate mRNA levels and enzyme activity 
assays. Total RNA was extracted using a Total RNA 
Extraction Miniprep kit (Viogene, Taiwan) based on  
the manufacturer’s protocol. The purity and 
concentration of RNA were assessed using a 
NanoDrop spectrophotometer .The complementary 
DNA (cDNA) was synthesized from DNase-treated 
RNA (1µg) using Revert Aid First Strand cDNA 
Synthesis kit (Thermo Scientific, Fermentas, USA). 
 The measurement of mRNA expression of 
MnSOD and catalase. The mRNA expression was 
evaluated using real-time PCR in a Rotor Gene real-
time thermocycler (Qiagen, Hilden, Germany) using  
specific primers for MnSOD, catalase and β-actin, 
purchased from Qiagen  in the presence of SYBR 
Green detection kit (Takara Bio, Ostu, Japan).The  
specificity of PCR products was confirmed by 
melting curve   analysis for each amplified product 
and  gel electrophoresis.  
The measurement of MnSOD enzyme 
activity. Mn-SOD ctivity was determined in PBMCs 
using a SOD activity (kit ADI-900-157; Enzo Life 
Sciences; USA) according to the manufacturer's 
instructions. The cells were washed with PBS and 
lysed with 1x cell extraction buffer supplemented 
with phenyl methyl sulphunyl fluride 
(PMSF)(Sigma) as described in kit protocol. 
MnSOD activity was assessed using preincubation of 
cell lysate with 1mM potassium cyanide (KCN) to 
inactivate other SOD isoforms. Protein concentration 
was determined using the method of Bradford. SOD 
activity data were expressed as units per microgram 
of protein. 
The measurement of catalase enzyme 
activity. Catalase activity in PMBCs was measured 
with the catalase assay kit (ab83464;Abcam, 
Cambridge, MA) according to the manufacturer's 
protocol. This kit is based on the function of sample 
catalase in decomposing H2O2 to water and H2O in 
the presence of an optimal concentration of H2O2. 
The unconverted H2O2 reacts with OxiRed probe to 
produce a product, which can be measured  
spectrophotometrically at 570nm. The cells were 
washed twice with PBS and lysed in the assay buffer 
(contained in kit) using sonication on ice. The 
resulting supernatant was collected after 
centrifugation. The catalase activity was reported as 
U/mg protein (units of Cat per mg of proteins), which 
is reversely proportional to the signal generated from 
product.  
The catalase activity was expressed 
based on the protein concentration of each 
treatment,which is determined by the Bradford assay. 
Statistical analysis. All data was analyzed using 
SPSS 19 (SPSS Inc., Chicago, IL, USA). Comparisons 
between patients and healthy subjects were done by 
the Student’s independent t test and results were 
presented as mean±standard error of the mean (SEM). 
Comparative CT method was used for analysis of the 
gene expression. Statistical significance was 
considered at a P<0.05. 
Results	
MnSOD and catalase mRNA expression in 
PBMCs from MS patients and healthy subjects. The 
results concerning mRNA level of MnSOD and 
catalase in PBMCs from MS patients and healthy 
subjects were depicted in figure1. As shown in this 
figure, the difference between healthy subjects and 
patients with RRMS for mRNA expression of MnSOD 
and catalase was statistically significant (P<0.05) . In 
healthy subjects, mRNA levels of MnSOD were 
higher compared with patients with RRMS (almost 2 
fold change),while we found an approximately 2 fold 
increase in mRNA expression of catalase in PBMCs 
from RRMS patients in comparison with that in 
healthy group. 
MnSOD and catalase enzyme activity in 
PBMCs from MS patients and healthy subjects. The 
enzyme activity of MnSOD and catalase in PBMCs 
from Patients with RRMS and healthy subjects were 
demonstrated in figure 2 and 3, respectively. MnSOD 
enzyme activity in PBMCs of MS patients (11.75±0.7 
U/mg of protein) was significantly lower in 
comparison with control group (20±2.23 U/mg of 
protein) (Figure 2). In case of catalase enzyme 
activity, a marked and significant increase was 
observed in enzyme activity of catalase in patients 
with RRMS (11.33±0.63 U/mg of protein) in 
comparison with healthy group (4.16±0.93 U/mg of 
protein) (Figure 3). 
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The main findings of our study are as follows: 
1) A significant increase in mRNA expression and 
activity of catalase  was observed in MS patients in 
comparison with healthy subjects; 2) A significant 
reduction in mRNA expression and activity of 
MnSOD was found in MS patients compared with 
controls. These results were in accordance with 
previous studies regarding the assessment of 
mentioned antioxidant enzymes in serum, lesions and 
CSF of MS patients. However, some studies found 
no significant difference with regard to MnSOD, 
catalase and others obviously observed different 
pattern in this regard.  
Pathologically, MS is characterized by 
infiltration of inflammatory cells including T- 
lymphocytes and monocyte-derived machrophages 
into CNS. One important consequence of leukocyte 
infiltration into the brain parenchyma is production 
of large amounts of ROS which result to neuronal 
damage, oligodendrocyte loss and myelin 
phagocytosis [16, 17]. 
Decrease in activity of SOD by either 
inhibition or reduced synthesis has been linked to 
uncontrolled production of oxygen free radicals 
(ROS), and increased permeability of blood brain 
barrier (BBB) [8, 18]. In other hand, ROS has been 
implicated in infiltrating immune cells via increase in 
BBB permeability. Notably, infiltrating leukocytes, 
themselves, by production of non-inflammatory 
mediators such as ROS, can contribute to myelin 
degeneration and axonal damage in a positive 
feedback loop [19, 20]. Hence, in light of the fact 
that decrease in activity of SOD can lead to increased 
concentration of free radical, particularly, super 
oxide anions, it is plausible that that the increased 
activity of catalase can be considered as an probable 
compensatory response for confronting oxidative 
stress–mediated damage in MS. Since it has been 
also demonstrated reduced level of Nrf2-regulated 
enzymes can exacerbate ROS-mediate tissue injury 
and contribute to myelin degeneration and glial 
activation [21, 22], our result of high enzyme activity 
of catalase can further reinforce this concept. 
Despite the considerable evidence linking the 
activity of antioxidant enzymes with presence and 
 
Figure 1. MnSOD and catalase mRNA fold change in PBMCs 
from patients with relapsing-remitting multiple sclerosis (RRMS) 
and healthy subjects. Data are expressed as means±SEM. P<0.05. 
 
 
Figure 3. Catalase enzyme activity in PBMCs from patients with 
relapsing-remitting multiple sclerosis (RRMS) and healthy 
subjects. Data are expressed as means±SEM. P<0.05. 
 
Figure 2. MnSOD enzyme activity in PBMCs from patients with 
relapsing-remitting multiple sclerosis (RRMS) and healthy 
subjects. Data are expressed as means±SEM. P<0.05. 
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extent of neuro-inflammation and oxidative injury, 
a large discrepancy observed in pattern of 
enzymatic and non-enzymatic antioxidants in MS, 
may be explained by a number of factors: MS 
presents a highly heterogeneity in term of clinical 
course of disease and also extent of severity, hence, 
it is conceivable that differences in patients 
included, can lead to distinct oxidative stress 
pattern. In addition, the choice of control groups is 
likely to offer a bias in results, and this was partly 
because all individuals endure mild levels of 
oxidative stress, particularly, when the control 
group selected from patients with other non-
inflammatory neurological disease. This concept 
strengthens when the control group selected from 
patients with other non-inflammatory neurological 
disease. Moreover, the use of different samples 
(CSF, peripheral blood cell, MS lesions and 
plasma) and also different techniques for assessing 
oxidative stress-related marker can be considered in 
this regard.  
In summary, our observations of 
dysregulated expression and activity of oxidative 
stress response-related genes, in PBMC of MS 
patients are considerable in several ways. Firstly, 
these results provide novel insights into the 
importance of regulation of oxidative stress in 
immune cells such as PBMCs. Secondly; it draws 
more attention to the regulation of oxidative stress 
pathway in PBMCs as a putative target for 
therapeutic intervention in oxidative stress–related 
disease. 
Accordingly, the present study can partly 
uncover obscure issues involved in role of oxidative 
stress in MS pathogenesis; however, 
some limitation of this study merits consideration 
here. From an ethical point of view, it is not possible 
to obtain a large amount of blood in order to isolate 
PBMC, therefore, we could not thoroughly 
investigate other important anti-oxidant enzymes in 
MS patients. Also, recruitment of other MS subtypes 
can be helpful to investigate role of oxidative stress 
in MS pathogenesis as a disease with highly variable 
picture. Therefore, further studies are required to 
fully establish the importance PBMCs in regulation 
of high oxidative stress-mediated tissue injury in MS 
as the known autoimmune disease. 
Conclusion	
It appears that impaired antioxidant enzymes in term of 
high activity of catalase and decreased activity of 
MnSOD are involved in MS pathogenesis, however 
further studies are needed to establish this concept. 
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